Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.89 USD
-0.68 (-1.72%)
Updated Sep 25, 2023 04:00 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 38% (93 out of 245)Zacks Sector Rank
Top 38% (6 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.70 | 1.35 | 9.99 |
Current Quarter Estimate | 0.74 | 7.43 | 55.00 |
Year Ago Quarter Estimate | 0.74 | 0.12 | 46.87 |
Next Quarter Estimate | 0.72 | 7.81 | 58.00 |
Next Year Estimate | 3.79 | 37.76 | 250.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 20.36 | 12.10 | 14.24 |
Next Year | 42.48 | 10.90 | 11.11 |
Last 5 Years | 35.00 | 11.70 | 9.00 |
Next 5 Years | 26.00 | 20.90 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 16.00 | -2.18 |
Price/Book (MRQ) | 33.91 | 1.65 |
Price/Cash Flow (MRFY) | 15.00 | 11.61 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 30.21% | -192.01% |
Return on Equity (TTM) | 254.75% | -57.29% |
Debt to Equity (MRQ) | 9.91 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.